oscotec inc (039200) Details

Oscotec Inc. engages in the development and manufacture of drugs for osteoporosis, arthritis, and periodontal diseases. The company’s product pipeline for osteoporosis disease includes OCT-1547 and OCT-SG815, which are anti-resorbing drugs; Wnt Stimulator, ODS-656, and ALK 4/7 Inhibitor that are bone-forming drugs; and PYK2 Inhibitor, a bone-reforming and anti-resorbing drug. Its product pipeline for arthritis disease consists of OCT-SG815, a bone destruction inhibitor; TCK-1, IL-23, and SYT inhibitors, which are anti-inflammation drugs; ADAMTS-5, a cartilage destruction inhibitor; and BT-201, an extracted material. The company also offers BT-301, an herb extract for the treatment of periodontal diseases. In addition, it provides research tool products, including OAAS and ELISA kits for biomedical companies, pharmaceutical companies, and research institutes. Further, the company manufactures nutraceutical products, including Osteopeak, Osteorus, Alveol, and PostPlant; and functional food ingredients, such as OsteoPeak proprietary blends, selected group additives, periodontal regeneration factor, and anti-inflammation factor for bone management. Additionally, it offers dental bone graft materials, including BioCera, BBP, SynCera, and AlloBone; dental membranes, which comprise CollaGuide; and dental supplies, such as PLACON, a dental centrifuge for platelet rich plasma technique in clinical trials. The company was founded in 1998 and is headquartered in Cheonan, the Republic of Korea.

oscotec inc (039200) Top Compensated Officers